Do you have further information concerning tesamorelin and its efficacy? I work for a company in the UK considering whether to introduce it here. Thanks for any guidance, Nick Foster

All you need to know is found is this link from the FDA: FDA briefing on tesamorelin (Egrifta)

Tesamorelin is called Egrifta in the United States and it is approve for the treatment of HIV related visceral fat. It is a growth hormone releasing hormone. It requires an injection under the skin daily and 30% of people do not gain any benefits from it. The other 60 % can get visceral fat reductions in the range of 17-26 percent in 26-48 weeks. It is expensive, at $2200 per month. When people stop using it, their fat comes back. It has not been studied in combination with exercise, diet or metformin.

It comes in 3 vials per day, which makes the preparation a bit tedious prior to every daily injection. Side effects are not as bad as the ones seen with Serostim ( a grown hormone approved for HIV wasting) but they could include joint aches and carpal tunnel syndrome. It does not seem to increase blood glucose as much as Serostim either.

The UK never approved Serostim even when people were dying with HIV wasting back in the 90's, so I doubt that Egrifta will be approved there. This link says it has been "pre-registed" there, though:

Tesamorelin in the UK

Nelson